Arnouk, Lara
Chantereau, Hélène
Courbage, Sophie
Tounian, Patrick
Clément, Karine
Poitou, Christine
Dubern, Béatrice http://orcid.org/0000-0002-0065-5344
Article History
Received: 5 August 2023
Accepted: 19 February 2024
First Online: 23 February 2024
Declarations
:
: All participants and their relatives signed a consent form to participate in the French Rare Obesity Cohorts With Food Behavioral Disorders: Better Diagnosis for Better Treatment (ObeRare) cohort (NCT04604626).
: Not Applicable.
: LA, HC, SC, and PT have nothing to disclose. BD has conference and expertise with Rhythm Pharmaceuticals and Novo-Nordisk and is a clinical investigator for Rhythm Pharmaceuticals. KC is a clinical investigator and performed conference and expertise for Rhythm Pharmaceuticals; a co-clinical investigator and has conference and expertise for Novo-Nordisk; and has collaborated on research for Integrative Phenomics and Confo Therapeutics; and performed conference and expertise with MSD. CP is the coordinator of the Oberar cohort, a clinical investigator and has conference and expertise for Novo-Nordisk and for Rhythm Pharmaceuticals.